N/A
N=12
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
Thrombocythemia · Myeloproliferative Disease · Thrombocytosis
Bottom Line
View on ClinicalTrials.gov: NCT02308787 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcome: Primary: Percent Change in Platelet (PLT) Count in Patient Blood Following Apheresis Procedure — -58.2 % change in PLT count in subject blood
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Spectra Optia Apheresis System (Device)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Terumo BCT
- Primary completion
- May 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Platelet (PLT) Count in Patient Blood Following Apheresis Procedure |
-58.2 | — |
| PRIMARY Percent of Processed Platelets (PLT) Which Are Collected i.e. Collection Efficiency for Platelets Achieved by Spectra Optia. |
67.8 | — |
| PRIMARY Adverse Events |
6 | — |
Summary
Multicenter, Retrospective Data Collection of Routine Clinical Use with the Spectra Optia® Apheresis System for Platelet Depletion Procedures.
Eligibility Criteria
Inclusion Criteria
- Patients having received a minimum of one platelet depletion procedure via the Spectra Optia system.
- Availability of complete blood count results prior to starting and after completing the platelet depletion procedure via the Spectra Optia system.
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT02308787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.